{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:49:48Z","timestamp":1777855788982,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hered Cancer Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hereditary breast and ovarian cancer (HBOC) confers a markedly increased lifetime risk of breast and ovarian cancers. As no effective surveillance method for early detection of ovarian cancer has been established, risk-reducing salpingo-oophorectomy (RRSO) is recommended for patients with HBOC to prevent disease onset. We evaluated the clinical characteristics of patients with HBOC and the surgical outcomes of RRSO performed at our institution.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed women diagnosed with HBOC at our institution between 2018 and 2024. For analyses of surgical outcomes, male patients, patients with prior bilateral adnexectomy, and patients diagnosed with HBOC who did not undergo RRSO were excluded. Clinical data including patient characteristics, surgical procedures, genetic testing, and pathological findings were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 283 women were diagnosed with HBOC, and 43 (15.1%) underwent testing based on the results of affected relatives. After excluding 39 patients with prior bilateral adnexectomy, and 105 who did not undergo RRSO, 139 patients were included in the surgical analysis. The uptake rate of RRSO among female patients with HBOC was 57%. The median age at surgery was 50\u2009years (range, 35\u201375). Pathogenic\n                      <jats:italic>BRCA1<\/jats:italic>\n                      variants were identified in 48 patients (34.5%),\n                      <jats:italic>BRCA2<\/jats:italic>\n                      variants in 90 (64.7%), and both\n                      <jats:italic>BRCA1<\/jats:italic>\n                      and\n                      <jats:italic>BRCA2<\/jats:italic>\n                      variants in 1 (0.7%). A history of malignancy was observed in 121 patients (breast cancer,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009121; pancreatic cancer,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091; ovarian cancer,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091; others,\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093). Laparoscopic RRSO was performed in 138 cases, with one additional hysterectomy performed laparoscopically and one via laparotomy. No perioperative complications were observed. All 6 cases before April 2020 were performed outside insurance coverage; after insurance coverage was initiated in April 2020, 16 were non-covered and 117 were covered by insurance. Pathological examination revealed occult high-grade serous carcinoma in 4 patients (2.9%) and serous tubal intraepithelial carcinoma in 5 patients (3.6%). To date, no cases of primary peritoneal carcinoma following RRSO have been identified.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RRSO was performed safely at our institution, with the detection rate of intraepithelial and invasive carcinoma comparable to previous reports. Although no cases of primary peritoneal carcinoma have been observed postoperatively to date, the residual risk remains, indicating the need for continued long-term surveillance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13053-026-00335-0","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T17:14:55Z","timestamp":1774113295000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A retrospective analysis of risk-reducing salpingo-oophorectomy performed in women diagnosed with hereditary breast and ovarian cancer at our institution"],"prefix":"10.1186","volume":"24","author":[{"given":"Yusaku","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Kitai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Akada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihide","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Yamabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reisa","family":"Kakubari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Hisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Kamiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"335_CR1","unstructured":"Japanese Organization for Hereditary Breast and Ovarian Cancer. Clinical practice guidelines for hereditary breast and ovarian cancer (HBOC). 3rd ed. Tokyo: Kanehara Shuppan; 2024."},{"key":"335_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/ng853","volume":"31","author":"PD Pharoah","year":"2002","unstructured":"Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet. 2002;31:33\u201336.","journal-title":"Nat Genet"},{"key":"335_CR3","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1136\/ijgc-2019-000384","volume":"29","author":"T Enomoto","year":"2019","unstructured":"Enomoto T, Aoki D, Hattori K, Jinushi M, Kigawa J, Takeshima N, et al. The first Japanese nationwide multi-center study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovariancancer geneTic TEsting of BRCA (CHARLOTTE). Int J Gynecol Cancer. 2019;29:1043\u201349.","journal-title":"Int J Gynecol Cancer"},{"key":"335_CR4","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1001\/jamaoncol.2022.0476","volume":"8","author":"Y Momozawa","year":"2022","unstructured":"Momozawa Y, Sasai R, Usui Y, Shiraishi K, Iwasaki Y, Taniyama Y, et al. Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants. JAMA Oncol. 2022;8:871\u201378.","journal-title":"JAMA Oncol"},{"key":"335_CR5","first-page":"CD012464","volume":"8","author":"GU Eleje","year":"2018","unstructured":"Eleje GU, Eke AC, Ezebialu IU, Ikechebulu JI, Ugwu EO, Okonkwo OO. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations. Cochrane Database Syst Rev. 2018;8:CD012464.","journal-title":"Cochrane Database Syst Rev"},{"key":"335_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","volume":"19","author":"MB Daly","year":"2021","unstructured":"Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, et al. Genetic\/Familial high-risk assessment: breast, ovarian, and pancreatic, version 2. 2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Network. 2021;19:77\u2013102.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"335_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41416-019-0446-1","volume":"121","author":"K Metcalfe","year":"2019","unstructured":"Metcalfe K, Eisen A, Senter L, Armel S, Bordeleau L, Meschino WS, et al. International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation. Br J Cancer. 2019;121(1):15\u201321.","journal-title":"Br J Cancer"},{"issue":"4","key":"335_CR8","first-page":"447","volume":"63","author":"A Masami","year":"2017","unstructured":"Masami A, Shiro Y, Chie W, Reiko Y, Mizuho K, Megumi O, et al. Genetic and clinical characteristics in Japanese hereditary breast and ovarian cancer: first report after establishment of HBOC registration system in Japan. J Hum Genet. 2017;63(4):447\u201357.","journal-title":"J Hum Genet"},{"issue":"3","key":"335_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.21873\/cdp.10325","volume":"4","author":"N Haruna","year":"2024","unstructured":"Haruna N, Sachiko M, Hirokazu T, Yui N, Mitsutoshi O, Yoko S, et al. High frequency of BRCA2 c.5576_5579del carriers in Kakogawa, Japan. Cancer Diagn Progn. 2024;4(3):309\u201314.","journal-title":"Cancer Diagn Progn"},{"key":"335_CR10","doi-asserted-by":"publisher","first-page":"112258","DOI":"10.18632\/oncotarget.22733","volume":"8","author":"A Hirasawa","year":"2017","unstructured":"Hirasawa A, Imoto I, Naruto T, Akahane T, Yamagami W, Nomura H, et al. Prevalence of pathogenic germline variants detected by multigene sequencing in unselected Japanese patients with ovarian cancer. Oncotarget. 2017;8:112258\u201367.","journal-title":"Oncotarget"},{"key":"335_CR11","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","volume":"372","author":"DF Easton","year":"2015","unstructured":"Easton DF, Pharoah PDP, Antiniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL, et al. Gene-panel sequencing study of hereditary ovarian cancer. N Engl J Med. 2015;372:2243\u201357.","journal-title":"N Engl J Med"},{"key":"335_CR12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.4069\/kjwhn.2020.11.19","volume":"26","author":"SY Park","year":"2020","unstructured":"Park SY, Kim Y, Kim S. Factors associated with the decision to undergo risk-reducing salpingo-oophorectomy among women at high risk for hereditary breast and ovarian cancer: a systematic review. Korean J Women Health Nurs. 2020;26:285\u201399.","journal-title":"Korean J Women Health Nurs"},{"key":"335_CR13","doi-asserted-by":"crossref","unstructured":"Singh K, Lester J, Karlan B, Bresee C, Geva T, Gordon O. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers. Am J Obstet Gynecol. 2013;208:329.e1\u2013e6.","DOI":"10.1016\/j.ajog.2013.01.026"},{"key":"335_CR14","doi-asserted-by":"publisher","first-page":"e067528","DOI":"10.1136\/bmj-2021-067528","volume":"375","author":"MC Cusimano","year":"2021","unstructured":"Cusimano MC, Chiu M, Ferguson SE, Moineddin R, Aktar S, Liu N, et al. Association of bilateral salpingo-oophorectomy with all-cause and cause-specific mortality: population based cohort study. BMJ. 2021;375:e067528.","journal-title":"BMJ"},{"key":"335_CR15","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1007\/s10147-021-02020-9","volume":"12","author":"H Nomura","year":"2021","unstructured":"Nomura H, Ikki A, Fusegi A, Omi M, Aoki Y, Netsu S, et al. Clinical and pathological outcomes of risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer. Int J Clin Oncol. 2021;12:2331\u201337.","journal-title":"Int J Clin Oncol"},{"key":"335_CR16","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/jjco\/hyaa173","volume":"51","author":"Y Kobayashi","year":"2021","unstructured":"Kobayashi Y, Hirasawa A, Chiyoda T, Ueki A, Masuda K, Misu K, et al. Retrospective evaluation of risk-reducing salpingo-oophorectomy for BRCA1\/2 pathogenic variant carriers among a cohort study in a single institution. Jpn J Clin Oncol. 2021;51:213\u201317.","journal-title":"Jpn J Clin Oncol"},{"key":"335_CR17","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1097\/IGC.0b013e3182a80ac8","volume":"23","author":"SL Wethington","year":"2013","unstructured":"Wethington SL, Park KJ, Soslow RA, Kauff ND, Brown CL, Dao F, et al. Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC). Int J Gynecol Cancer. 2013;23:1603\u201311.","journal-title":"Int J Gynecol Cancer"},{"key":"335_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/jnci\/djn442","volume":"101","author":"TR Rebbeck","year":"2009","unstructured":"Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst. 2009;101:80\u201387.","journal-title":"J Natl Cancer Inst"},{"key":"335_CR19","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.2013.53.2820","volume":"32","author":"AP Finch","year":"2014","unstructured":"Finch AP, Lubinski J, Moller P, Singer CF, Karlan B, Senter L, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32:1547\u201353.","journal-title":"J Clin Oncol"},{"key":"335_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1001\/jama.296.2.185","volume":"296","author":"A Finch","year":"2006","unstructured":"Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, et al. Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oopho-rectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA. 2006;296:185\u201392.","journal-title":"JAMA"},{"key":"335_CR21","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1159\/000479155","volume":"93","author":"L Cortesi","year":"2017","unstructured":"Cortesi L, De Matteis E, Toss A, Marchi I, Medici V, Contu G, et al. Evaluation of transvaginal ultrasound plus CA-125 measurement and prophylactic salpingo-oophorectomy in women at different risk levels of ovarian cancer: the Modena study group cohort study. Oncology. 2017;93:377\u201386.","journal-title":"Oncology"},{"key":"335_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ygyno.2024.05.010","volume":"187","author":"CB Van den Berg","year":"2024","unstructured":"Van den Berg CB, Dasgupta S, Ewing-Graham PC, Bart J, Bulten J, Gaarenstroom KN, et al. Does serous tubal intraepithelial carcinoma (STIC) metastasize? The clonal relationship between STIC and subsequent high-grade serous carcinoma in BRCA1\/2 mutation carriers several years after risk-reducing salpingo-oophorectomy. Gynecol Oncol. 2024;187:113\u201319.","journal-title":"Gynecol Oncol"},{"key":"335_CR23","unstructured":"Japan Society of Gynecologic Oncology. Guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. 6th ed. Tokyo: Kanehara Shuppan; 2025."},{"key":"335_CR24","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1200\/JCO.21.02016","volume":"40","author":"MP Steenbeek","year":"2022","unstructured":"Steenbeek MP, van Bommel MHD, Bulten J, Hulsmann JA, Bogaerts J, Garsia C, et al. Risk of peritoneal carcinomatosis after risk-reducing salpingo-oophorectomy: a systematic review and individual patient data meta-analysis. J Clin Oncol. 2022;40:1879\u201391.","journal-title":"J Clin Oncol"},{"key":"335_CR25","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/cncr.31211","volume":"124","author":"MG Harmsen","year":"2018","unstructured":"Harmsen MG, Piek JMJ, Bulten J, Casey MJ, Rebbeck TR, Mourits MJ, et al. Peritoneal carcinomatosis after risk-reducing surgery in BRCA1\/2 mutation carriers. Cancer. 2018;124:952\u201359.","journal-title":"Cancer"},{"key":"335_CR26","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/SAP.0b013e3181a2c6bd","volume":"64","author":"WJ Casey 3rd","year":"2010","unstructured":"Casey WJ 3rd, Rebecca AM, Andres LA, Craft RO, Smith AA, Pockaj BA, et al. Safety and efficacy of perforator flap breast reconstruction with combined intraabdominal procedures. Ann Plast Surg. 2010;64:144\u201350.","journal-title":"Ann Plast Surg"},{"key":"335_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/1471-2407-8-101","volume":"8","author":"LI Batista","year":"2008","unstructured":"Batista LI, Lu KH, Beahm EK, Arun BK, Bodurka DC, Meric-Bernstam F. Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. BMC Cancer. 2008;8:101.","journal-title":"BMC Cancer"},{"key":"335_CR28","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1001\/jamaoncol.2016.1820","volume":"2","author":"CA Shu","year":"2016","unstructured":"Shu CA, Pike MC, Jotwani AR, Friebel TM, Soslow RA, Levine DA, et al. Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA Oncol. 2016;2:1134\u201340.","journal-title":"JAMA Oncol"}],"container-title":["Hereditary Cancer in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13053-026-00335-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-026-00335-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-026-00335-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:30:13Z","timestamp":1777505413000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13053-026-00335-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["335"],"URL":"https:\/\/doi.org\/10.1186\/s13053-026-00335-0","relation":{},"ISSN":["1897-4287"],"issn-type":[{"value":"1897-4287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed and approved by the Research Ethics Committee of Osaka International Cancer Institute (No. 24187).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No patient consent for publication was required as this study does not include any identifiable patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}